Roger A. Von Moos
Chur, GR, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 126 publications
Immune-related adverse events of immune checkpoint inhibitors
Journal: Therapeutische Umschau. Revue therapeutique
Published: September 01, 2026
The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma.
Journal: Swiss medical weekly
Published: August 14, 2025
Breast cancer incidence, by stage at diagnosis, and mortality in 21 European countries in the era of mammography screening: an international population-based study.
Journal: The Lancet regional health. Europe
Published: August 12, 2025
A retrospective analysis of phase I and phase I/II investigator-initiated clinical trials conducted by the Swiss Group for Clinical Cancer Research (SAKK).
Journal: ESMO open
Published: May 29, 2025
Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA).
Journal: Melanoma research
Published: April 23, 2025
Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer.
Journal: Clinical breast cancer
Published: February 15, 2025
A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland.
Journal: Swiss medical weekly
Published: January 21, 2025
Correction: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
Journal: PloS one
Published: December 12, 2024
Long-term survival for myeloid neoplasms and national health expenditure: A EUROCARE-6 retrospective, population-based study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 09, 2024
Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study.
Journal: ESMO open
Published: July 31, 2024
Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study.
Journal: Bone reports
Published: April 19, 2024
Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences study.
Journal: Cancer
Published: March 15, 2024
Last Updated: 09/26/2026